Ixarola 15 Mg/Ixarola 20 Mg Pi 15mg/ 20mg FC tablets
PDF Leaflet Revision Date: 12 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of stroke in non-valvular atrial fibrillation, treatment and prevention of DVT and PE.
Dosage (summary)
SPAF: 20 mg once daily; DVT/PE: 15 mg twice daily for 3 weeks, then 20 mg once daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may cause bleeding.
Key Drug Interactions
- Strong CYP 3A4 and P-gp inhibitors
- NSAIDs
- Anticoagulants
Contraindications
- Active bleeding
- Severe hepatic impairment
- Hypersensitivity to rivaroxaban
Common side effects
- Bleeding
- Anemia
- Dizziness
Counselling Points
- Take with food
- Monitor for signs of bleeding
- Do not double doses for missed doses
Serious warnings
- Risk of thrombotic events with premature discontinuation
- Spinal/epidural hematoma risk
Important Disclaimer
The Ixarola 15 Mg/Ixarola 20 Mg Pi 15mg/ 20mg FC tablets professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
